Literature DB >> 17475490

Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale.

M L C Hagemans1, P Laforêt, W J C Hop, I S J Merkies, P A Van Doorn, A J J Reuser, A T Van der Ploeg.   

Abstract

With the recent approval of enzyme replacement therapy for Pompe disease, insight into the social consequences of this disorder becomes even more relevant. The aim of this study was to measure the impact of late-onset Pompe disease on participation in daily life activities and to evaluate the applicability of the Rotterdam Handicap Scale (RHS) for use in Pompe disease. Two hundred fifty-seven adult patients from different countries participated in the study. The mean RHS score was 25.9+/-6.5 on a scale of 9-36. Individual item scores were lowest for 'domestic tasks indoors', 'domestic tasks outdoors', and 'work/study'. The mean RHS score differed significantly between patients with and without respiratory support (22.9 vs. 28.5, p<0.001) and patients with and without a wheelchair (20.9 vs. 29.5, p<0.001). No differences in RHS score were found between countries. The RHS showed good internal consistency and excellent Test-retest reliability. A ceiling effect of 8% was present. We conclude that the RHS seems suitable for this patient population and that Pompe disease has a large impact on the participation in daily life activities, in particular on the ability of patients to fulfil their work or study.

Entities:  

Mesh:

Year:  2007        PMID: 17475490     DOI: 10.1016/j.nmd.2007.03.006

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  14 in total

1.  Qualitative and quantitative skeletal muscle ultrasound in late-onset acid maltase deficiency.

Authors:  Craig M Zaidman; Elizabeth C Malkus; Catherine Siener; Julaine Florence; Alan Pestronk; Muhammad Al-Lozi
Journal:  Muscle Nerve       Date:  2011-07-13       Impact factor: 3.217

Review 2.  [Diagnosis and therapy of late onset Pompe disease].

Authors:  A Schüller; C Kornblum; M Deschauer; M Vorgerd; B Schrank; E Mengel; Z Lukacs; D Gläser; P Young; U Plöckinger; B Schoser
Journal:  Nervenarzt       Date:  2013-12       Impact factor: 1.214

3.  Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease.

Authors:  J C van der Meijden; D Güngör; M E Kruijshaar; A D J Muir; H A Broekgaarden; A T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2014-08-12       Impact factor: 4.982

4.  Fatigue in spinocerebellar ataxia: patient self-assessment of an early and disabling symptom.

Authors:  Esther Brusse; Marjolein G J Brusse-Keizer; Hugo J Duivenvoorden; John C van Swieten
Journal:  Neurology       Date:  2011-03-15       Impact factor: 9.910

Review 5.  A Multidisciplinary Perspective Addressing the Diagnostic Challenges of Late-Onset Pompe Disease in the Arabian Peninsula Region Developed From an Expert Group Meeting.

Authors:  Ali Al Shehri; Abdullah Al-Asmi; Abdullah Mohammed Al Salti; Abubaker Almadani; Ali Hassan; Ahmed K Bamaga; Edward J Cupler; Jasem Al-Hashel; Majed M Alabdali; Mohammed H Alanazy; Suzan Noori
Journal:  J Neuromuscul Dis       Date:  2022

6.  Progress in Enzyme Replacement Therapy in Glycogen Storage Disease Type II.

Authors:  Corrado Angelini; Claudio Semplicini; Paola Tonin; Massimiliano Filosto; Elena Pegoraro; Gianni Sorarù; Marina Fanin
Journal:  Ther Adv Neurol Disord       Date:  2009-05       Impact factor: 6.570

7.  Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy.

Authors:  Deniz Güngör; Juna M de Vries; Wim C J Hop; Arnold J J Reuser; Pieter A van Doorn; Ans T van der Ploeg; Marloes L C Hagemans
Journal:  Orphanet J Rare Dis       Date:  2011-06-01       Impact factor: 4.123

8.  The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients.

Authors:  Carine I van Capelle; Nadine A M E van der Beek; Juna M de Vries; Pieter A van Doorn; Hugo J Duivenvoorden; Robert T Leshner; Marloes L C Hagemans; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2011-09-13       Impact factor: 4.982

9.  A conceptual disease model for adult Pompe disease.

Authors:  Tim A Kanters; W Ken Redekop; Maureen P M H Rutten-Van Mölken; Michelle E Kruijshaar; Deniz Güngör; Ans T van der Ploeg; Leona Hakkaart
Journal:  Orphanet J Rare Dis       Date:  2015-09-15       Impact factor: 4.123

10.  Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up.

Authors:  Deniz Güngör; Michelle E Kruijshaar; Iris Plug; Dimitris Rizopoulos; Tim A Kanters; Stephan C A Wens; Arnold J J Reuser; Pieter A van Doorn; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2015-11-03       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.